JP2019513725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513725A5 JP2019513725A5 JP2018552062A JP2018552062A JP2019513725A5 JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5 JP 2018552062 A JP2018552062 A JP 2018552062A JP 2018552062 A JP2018552062 A JP 2018552062A JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- binds
- immune checkpoint
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 7
- 108010073807 IgG Receptors Proteins 0.000 claims 6
- 102000009490 IgG Receptors Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 108010021470 Fc gamma receptor IIC Proteins 0.000 claims 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 5
- 102100029206 Low affinity immunoglobulin gamma Fc region receptor II-c Human genes 0.000 claims 5
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 5
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 5
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 4
- 206010064390 Tumour invasion Diseases 0.000 claims 4
- 230000009400 cancer invasion Effects 0.000 claims 4
- 210000003289 regulatory T cell Anatomy 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 102100026197 C-type lectin domain family 2 member D Human genes 0.000 claims 1
- 102100038078 CD276 antigen Human genes 0.000 claims 1
- -1 CD86 Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 claims 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605947 | 2016-04-07 | ||
| GB1605947.9 | 2016-04-07 | ||
| PCT/EP2017/056469 WO2017174331A1 (en) | 2016-04-07 | 2017-03-17 | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513725A JP2019513725A (ja) | 2019-05-30 |
| JP2019513725A5 true JP2019513725A5 (enExample) | 2020-04-23 |
| JP7325959B2 JP7325959B2 (ja) | 2023-08-15 |
Family
ID=58358618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552062A Active JP7325959B2 (ja) | 2016-04-07 | 2017-03-17 | 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190135925A1 (enExample) |
| EP (1) | EP3440109B1 (enExample) |
| JP (1) | JP7325959B2 (enExample) |
| KR (2) | KR20220032642A (enExample) |
| CN (1) | CN109476739A (enExample) |
| AU (1) | AU2017247880B2 (enExample) |
| BR (1) | BR112018070636A2 (enExample) |
| CA (1) | CA3020204A1 (enExample) |
| CL (2) | CL2018002828A1 (enExample) |
| ES (1) | ES3046543T3 (enExample) |
| IL (1) | IL262129B2 (enExample) |
| MX (1) | MX2018012319A (enExample) |
| PL (1) | PL3440109T3 (enExample) |
| RU (1) | RU2759970C2 (enExample) |
| WO (1) | WO2017174331A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| EP3440109B1 (en) | 2016-04-07 | 2025-07-23 | Cancer Research Technology Limited | Anti cd25 fc gamma receptor antibodies for tumor specific cell depletion in combination with pd-1 antagonists |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| AU2019207767B2 (en) * | 2018-01-10 | 2025-09-18 | Bioinvent International Ab | Novel combination and use of antibodies |
| US12037410B2 (en) * | 2018-02-13 | 2024-07-16 | Precision Biologics, Inc. | Methods and compositions for targeting Treg cells |
| AU2019233581B2 (en) * | 2018-03-13 | 2025-08-28 | Cancer Research Technology Limited | Anti-CD25 for tumour specific cell depletion |
| EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| WO2020028269A2 (en) * | 2018-07-30 | 2020-02-06 | Invenra Inc. | Multispecific treg binding molecules |
| WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
| EP4103611B1 (en) * | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
| CA3182362A1 (en) * | 2020-05-14 | 2021-11-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
| KR20230107641A (ko) | 2020-11-13 | 2023-07-17 | 아이바이오, 인크. | Cd25 항체 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| TW202319400A (zh) | 2021-09-02 | 2023-05-16 | 瑞士商赫孚孟拉羅股份公司 | 用於治療aml之抗體 |
| TW202336033A (zh) * | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| EP4514388A1 (en) | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024151091A1 (ko) * | 2023-01-11 | 2024-07-18 | 한국과학기술원 | 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| WO2024165454A1 (en) | 2023-02-06 | 2024-08-15 | F. Hoffmann-La Roche Ag | Combination therapy and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013677B1 (ru) * | 2002-11-15 | 2010-06-30 | Генмаб А/С | Человеческие моноклональные антитела против cd25 и их применение |
| GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| WO2008085562A2 (en) * | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| WO2010030002A1 (ja) * | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| CA3093606A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| EP3440109B1 (en) | 2016-04-07 | 2025-07-23 | Cancer Research Technology Limited | Anti cd25 fc gamma receptor antibodies for tumor specific cell depletion in combination with pd-1 antagonists |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| AU2019233581B2 (en) * | 2018-03-13 | 2025-08-28 | Cancer Research Technology Limited | Anti-CD25 for tumour specific cell depletion |
| EP4514388A1 (en) * | 2022-04-26 | 2025-03-05 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist |
-
2017
- 2017-03-17 EP EP17711664.7A patent/EP3440109B1/en active Active
- 2017-03-17 WO PCT/EP2017/056469 patent/WO2017174331A1/en not_active Ceased
- 2017-03-17 US US16/091,350 patent/US20190135925A1/en not_active Abandoned
- 2017-03-17 PL PL17711664.7T patent/PL3440109T3/pl unknown
- 2017-03-17 JP JP2018552062A patent/JP7325959B2/ja active Active
- 2017-03-17 KR KR1020227006876A patent/KR20220032642A/ko not_active Ceased
- 2017-03-17 RU RU2018135247A patent/RU2759970C2/ru active
- 2017-03-17 IL IL262129A patent/IL262129B2/en unknown
- 2017-03-17 KR KR1020187032183A patent/KR20190017735A/ko not_active Ceased
- 2017-03-17 CA CA3020204A patent/CA3020204A1/en active Pending
- 2017-03-17 AU AU2017247880A patent/AU2017247880B2/en active Active
- 2017-03-17 BR BR112018070636-1A patent/BR112018070636A2/pt unknown
- 2017-03-17 CN CN201780022552.4A patent/CN109476739A/zh active Pending
- 2017-03-17 ES ES17711664T patent/ES3046543T3/es active Active
- 2017-03-17 MX MX2018012319A patent/MX2018012319A/es unknown
-
2018
- 2018-10-04 CL CL2018002828A patent/CL2018002828A1/es unknown
-
2019
- 2019-11-29 CL CL2019003498A patent/CL2019003498A1/es unknown
-
2022
- 2022-03-28 US US17/706,028 patent/US20230265200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513725A5 (enExample) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2020514363A5 (enExample) | ||
| US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019500891A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2019500892A5 (enExample) | ||
| JP2020514363A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| JP2018520657A5 (enExample) | ||
| KR20160037989A (ko) | 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합 | |
| IL263611A (en) | Antibodies specific to PD-L1 and methods of using them | |
| JP2017537892A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2020502147A5 (enExample) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2019518721A5 (enExample) | ||
| CN111542544A (zh) | 用于治疗癌症的免疫刺激性激动性抗体 | |
| JP2018528776A5 (enExample) | ||
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2020528765A5 (enExample) | ||
| WO2021080920A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| JPWO2019195452A5 (enExample) |